Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Apellis Pharmaceuticals, Inc. (APLS) InvestorsBusiness Wire • 08/15/23
APLS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc. ShareholdersPRNewsWire • 08/15/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Apellis Pharmaceuticals, Inc. (APLS) InvestorsBusiness Wire • 08/14/23
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023PRNewsWire • 08/14/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of InvestorsBusiness Wire • 08/11/23
APLS SHAREHOLDER ALERT: Jakubowitz Law Reminds Apellis Shareholders of a Lead Plaintiff Deadline of October 2, 2023PRNewsWire • 08/11/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of InvestorsBusiness Wire • 08/10/23
The Law Offices of Frank R. Cruz Announces Investigation of Apellis Pharmaceuticals, Inc. (APLS) on Behalf of InvestorsBusiness Wire • 08/10/23
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLSPRNewsWire • 08/10/23
Apellis Pharmaceuticals, Inc. (APLS) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Apellis Pharmaceuticals, Inc. Class ActionBusiness Wire • 08/09/23
APELLIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 08/08/23
ROSEN, A TOP RANKED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – APLSBusiness Wire • 08/07/23
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The ChinInvestors Business Daily • 08/07/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $750,000 to Contact the FirmAccesswire • 08/06/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $750,000 to Contact the FirmAccesswire • 08/05/23
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLSPRNewsWire • 08/04/23
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLSBusiness Wire • 08/04/23
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Apellis Pharmaceuticals, Inc. (APLS)Business Wire • 08/03/23
APLS INVESTOR ALERT: KESSLER TOPAZ MELTZER & CHECK, LLP AND BERNSTEIN LITOWITZ BERGER & GROSSMANN LLP ANNOUNCE THE FILING OF A SECURITIES FRAUD CLASS ACTION LAWSUIT AGAINST APELLIS PHARMACEUTICALS, INC. AND ENCOURAGE INVESTORS WITH SUBSTANTIAL LOSSES TO CPRNewsWire • 08/03/23
APLS Investor Alert: Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce the Filing of a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.Business Wire • 08/02/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the FirmAccesswire • 08/02/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the FirmAccesswire • 08/01/23
Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales BeatInvestors Business Daily • 07/31/23
